Importantly, recombinant FKN and tumor‐expressed FKN are efficacious in delaying tumor growth in vivo locally and systemically, indicating a potential therapeutic use of FKN in combination with immunotherapy. The gene discussed is CX3CL1; the disease is neoplasm.